Table 1.
Patient characteristics
| RP (n = 62) | RT (n = 62) | P-value | |
|---|---|---|---|
| Clinical T stage | NA | ||
| T1 | 36 | 36 | |
| T2 | 23 | 23 | |
| T3 | 3 | 3 | |
| PSA | NA | ||
| <10 | 30 | 30 | |
| 10-20 | 5 | 5 | |
| >20 | 27 | 27 | |
| Biopsy Gleason score | NA | ||
| 6 or 7 | 17 | 17 | |
| 8 | 30 | 30 | |
| 9 or 10 | 15 | 15 | |
| ACE-27 | .52 | ||
| 0 | 15 | 10 | |
| 1 | 30 | 32 | |
| ≥2 | 17 | 20 | |
| Age (years) | .492 | ||
| Mean | 62.9 | 64.2 | |
| Standard deviation | 7.1 | 9.1 | |
| Follow-up (months)* | .004 | ||
| Median | 41 | 51.4 | |
| Standard deviation | 26.5 | 29.8 | |
| Days to Treatment from Dx | < .001 | ||
| Median | 56 | 131.5 | |
| Standard deviation | 29 | 299 |
ACE-27, Adult Comorbidity Evaluation-27; Dx, diagnosis; NA, not applicable; PSA, prostate-specific antigen; RP, radical prostatectomy; RT, radiation therapy.
*
Calculated from the completion of RT or date of RP.